Veru announces acceptance of two abstracts for presentation at the 39th miami breast cancer conference

Miami, march 04, 2022 (globe newswire) -- veru inc. (nasdaq: veru), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers, today announced that two abstracts were accepted for presentation at the 39th miami breast cancer conference being held march 3-6, 2022, at the fontainebleau miami beach.
VERU Ratings Summary
VERU Quant Ranking